Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 47.7% in July

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 15,800 shares, a growth of 47.7% from the June 30th total of 10,700 shares. Based on an average daily volume of 58,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Archford Capital Strategies LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 59.1% during the second quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after buying an additional 13,703 shares during the last quarter. James J. Burns & Company LLC bought a new position in shares of Global X Genomics & Biotechnology ETF during the second quarter valued at about $181,000. Insight Advisors LLC PA grew its stake in shares of Global X Genomics & Biotechnology ETF by 59.0% during the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after buying an additional 7,861 shares during the last quarter. Portland Global Advisors LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 0.6% during the first quarter. Portland Global Advisors LLC now owns 242,090 shares of the company’s stock valued at $2,755,000 after buying an additional 1,450 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Global X Genomics & Biotechnology ETF by 16.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock valued at $4,431,000 after buying an additional 53,178 shares during the last quarter. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

NASDAQ GNOM traded down $0.09 during trading hours on Monday, reaching $11.63. 41,555 shares of the stock traded hands, compared to its average volume of 63,355. The stock has a 50 day simple moving average of $10.71 and a two-hundred day simple moving average of $10.90. Global X Genomics & Biotechnology ETF has a 1 year low of $8.63 and a 1 year high of $12.53. The company has a market cap of $86.53 million, a price-to-earnings ratio of -4.97 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.